PACIFIC 5-Yr Update - Capsule Summary Slidesets - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
PACIFIC survival explained: Cancer spread red | EurekAlert!
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Nathan A. Pennell MD, PhD, FASCO on Twitter: "The PACIFIC trial of consolidation durvalumab starting up to 42 days after concurrent chemoradiation for unresectable stage 3 NSCLC is already SOC due to
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
First-line Durvalumab Improves Survival
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
First-line Durvalumab Improves Survival
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
